Eaton Vance Worldwide Health Sciences Fund A (ETHSX)
14.27
+0.03
(+0.21%)
USD |
Oct 27 2026
Returns Chart
Key Stats
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 1.18% | 779.02M | 1.59% | -- |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -128.71M | 13.26% |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital growth by investing in a global, diversified portfolio of securities of health science companies. The Fund normally invests at least 80% of its assets in securities of companies primarily engaged in the discovery, development, production or distribution of products related to health care. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Large Cap Core |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Global Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | World Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Global Health/Biotechnology Funds |
| Fund Owner Firm Name | Eaton Vance |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
83
-222.74M
Peer Group Low
118.32M
Peer Group High
1 Year
% Rank:
81
-128.71M
-4.396B
Peer Group Low
302.98M
Peer Group High
3 Months
% Rank:
71
-823.76M
Peer Group Low
318.28M
Peer Group High
3 Years
% Rank:
49
-15.99B
Peer Group Low
369.95M
Peer Group High
6 Months
% Rank:
81
-2.012B
Peer Group Low
361.10M
Peer Group High
5 Years
% Rank:
41
-21.95B
Peer Group Low
463.25M
Peer Group High
YTD
% Rank:
67
-3.040B
Peer Group Low
985.68M
Peer Group High
10 Years
% Rank:
64
-42.91B
Peer Group Low
908.40M
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of October 28, 2026.
Asset Allocation
As of August 31, 2026.
| Type | % Net |
|---|---|
| Cash | 0.38% |
| Stock | 99.08% |
| Bond | 0.30% |
| Convertible | 0.00% |
| Preferred | 0.00% |
| Other | 0.24% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Eli Lilly & Co. | 11.97% | 1281.91 | 0.22% |
| Johnson & Johnson | 7.15% | 268.73 | 0.91% |
| AbbVie, Inc. | 7.15% | 286.39 | -0.12% |
| Merck & Co., Inc. | 5.95% | 141.82 | 0.86% |
| Roche Holding AG | 5.30% | 480.61 | 2.24% |
| UnitedHealth Group, Inc. | 5.29% | 410.39 | -0.08% |
| AstraZeneca PLC | 4.28% | 170.08 | -1.15% |
| Bristol Myers Squibb Co. | 4.26% | 61.55 | -0.10% |
| Vertex Pharmaceuticals, Inc. | 3.83% | 521.03 | 0.68% |
| Abbott Laboratories | 3.29% | 103.10 | -1.70% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | 0.25% |
| Actual Management Fee | 0.77% |
| Administration Fee | 976856.0 None |
| Maximum Front Load | 5.25% |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | 0.00% |
| General Availability | |
| Available for Insurance Product | No |
| Available for RRSP | No |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 1000.00 None |
| Minimum Subsequent Investment | 0.00 None |
TTM Distributions
| Type | Oct | Nov | Dec | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Qualified Income
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Normal
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Qualified
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
LT Cap Gains
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Ordinary Income
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Non-Qual
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
ST Cap Gains
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Interest
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Tax-Exempt
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
ROC
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Other
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Total
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
As of September 30, 2026.
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital growth by investing in a global, diversified portfolio of securities of health science companies. The Fund normally invests at least 80% of its assets in securities of companies primarily engaged in the discovery, development, production or distribution of products related to health care. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Large Cap Core |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Global Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | World Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Global Health/Biotechnology Funds |
| Fund Owner Firm Name | Eaton Vance |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (10-27-26) | 0.51% |
| 30-Day SEC Yield (12-31-88) | -2.37% |
| 7-Day SEC Yield | -- |
| Number of Holdings | 42 |
| Stock | |
| Weighted Average PE Ratio | 34.51 |
| Weighted Average Price to Sales Ratio | 6.953 |
| Weighted Average Price to Book Ratio | 9.021 |
| Weighted Median ROE | 483.1% |
| Weighted Median ROA | 8.60% |
| Return on Investment (TTM) | 12.50% |
| Earning Yield | 0.0337 |
| LT Debt / Shareholders Equity | 0.7887 |
| Number of Equity Holdings | 40 |
As of August 31, 2026
Growth Metrics
| EPS Growth (1Y) | 35.38% |
| EPS Growth (3Y) | 13.88% |
| EPS Growth (5Y) | 14.60% |
| Sales Growth (1Y) | 14.94% |
| Sales Growth (3Y) | 10.59% |
| Sales Growth (5Y) | 11.18% |
| Sales per Share Growth (1Y) | 19.05% |
| Sales per Share Growth (3Y) | 11.22% |
| Operating Cash Flow - Growth Rate (3Y) | 6.80% |
As of August 31, 2026
Fund Details
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:ETHSX", "name") |
| Broad Asset Class: =YCI("M:ETHSX", "broad_asset_class") |
| Broad Category: =YCI("M:ETHSX", "broad_category_group") |
| Prospectus Objective: =YCI("M:ETHSX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |